Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome
Alzheimer's & Dementia · 2025-10 · 21 (10)
DOI: 10.1002/alz.70726 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 27.09.2025. Verfasst von Natalie C Edwards und 25 weiteren Autor:innen. Beteiligte Einrichtung: Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York City, New York, USA. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, Cerebrovascular Disorders, Neuroinflammatory Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NICHD NIH HHS, NCATS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Despite having few vascular risk factors, people with Down syndrome (DS) have MRI evidence of cerebrovascular disease (CVD) and neuroinflammation that worsens with Alzheimer's disease (AD) severity. We investigated whether markers of CVD and inflammation are associated with AD‐related diagnostic progression in people with DS. METHODS We included 149 participants (mean age [SD] = 44.6 [9]) from the Alzheimer's Biomarkers Consortium–Down Syndrome who had two ( n = 24) or three follow‐up visits ( n = 125). We derived white matter hyperintensity (WMH) volume and plasma biomarker (glial fibrillary acidic protein [GFAP], amyloid beta [Aβ]42/Aβ40, hyperphosphorylated tau‐217 [p‐tau217], and neurofilament light [NfL]) concentrations at baseline and examined their association with progression in clinical diagnosis. RESULTS Higher baseline WMH volume and higher GFAP were associated with a greater likelihood of diagnostic progression. Combining WMH and GFAP with p‐tau217 improved clinical conversion classification accuracy over AD biomarkers alone. Among individuals with evidence of amyloidosis, both WMH and GFAP were associated with clinical progression. DISCUSSION In DS, markers of CVD and inflammation are independently and synergistically associated with clinical AD progression. Highlights Higher baseline white matter hyperintensity (WMH) volume and plasma glial fibrillary acidic protein (GFAP) concentration were associated with a higher likelihood of progressing from cognitively stable to either mild cognitive impairment or clinical Alzheimer's disease in Down syndrome. WMH volume and GFAP concentration discriminated between those who progressed and those who did not. Models including the independent and interactive effects of WMH and GFAP more accurately discriminated between participants who progressed diagnostically from those who did not. Individuals with evidence of amyloid pathology were more likely to progress if they also had elevated WMH or GFAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York City, New York, USA.
- Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA.
- Department of Neuroscience, Columbia University, New York City, New York, USA.
- Department of Neurobiology & Behavior, University of California, Irvine, California, USA.
- University of North Texas Health Science Center, Fort Worth, Texas, USA.
- Department of Pathology and Laboratory Medicine, University of California Irvine School of Medicine, University of California, Irvine, California, USA.
Förderung
- NIA NIH HHS
- NICHD NIH HHS
- NCATS NIH HHS
- DS-Connect (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health programs: The Alzheimer's Disease Research Centers program
- National Centralized Repository for Alzheimer's Disease and Related Dementias
- NIHR Cambridge Biomedical Research Centre and the Windsor Research Unit, CPFT, Fulbourn Hospital Cambridge
- National Center for Advancing Translational Sciences
Zitieren
APA
Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B., Petersen, M. E., O'Bryant, S., Flores-Aguilar, L., Simoes, S., Mapstone, M., Tudorascu, D. L., Janelidze, S., Hansson, O., Handen, B. L., Christian, B. T., Lee, J. H., Lai, F., Rosas, H. D., Zaman, S., …, & Brickman, A. M. (2025). Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70726
Vancouver
Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME, et al. Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70726
BibTeX
@article{Edwards2025,
author = {Edwards, Natalie C and Lao, Patrick J and Alshikho, Mohamad J and Ericsson, Olivia M and Rizvi, Batool and Petersen, Melissa E and O'Bryant, Sid and Flores-Aguilar, Lisi and Simoes, Sabrina and Mapstone, Mark and Tudorascu, Dana L and Janelidze, Shorena and Hansson, Oskar and Handen, Benjamin L and Christian, Bradley T and Lee, Joseph H and Lai, Florence and Rosas, H Diana and Zaman, Shahid and Lott, Ira T and Yassa, Michael A and Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators, Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators and Gutierrez, José and Wilcock, Donna M and Head, Elizabeth and Brickman, Adam M},
title = {Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {10},
doi = {10.1002/alz.70726}
}
EUVIMED